94 181

Cited 16 times in

First-in-human phase 1/1b study to evaluate sitravatinib in patients with advanced solid tumors

Authors
 Todd Bauer  ;  Byong Chul Cho  ;  Rebecca Heist  ;  Lyudmila Bazhenova  ;  Theresa Werner  ;  Sanjay Goel  ;  Dong-Wan Kim  ;  Douglas Adkins  ;  Richard D Carvajal  ;  Ajjai Alva  ;  Keith Eaton  ;  Judy Wang  ;  Yong Liu  ;  Xiaohong Yan  ;  Jamie Christensen  ;  Saskia Neuteboom  ;  Richard Chao  ;  Shubham Pant 
Citation
 INVESTIGATIONAL NEW DRUGS, Vol.40(5) : 990-1000, 2022-10 
Journal Title
INVESTIGATIONAL NEW DRUGS
ISSN
 0167-6997 
Issue Date
2022-10
MeSH
Anilides* / adverse effects ; Carcinoma, Non-Small-Cell Lung / drug therapy ; Humans ; Lung Neoplasms / drug therapy ; Neoplasms* / drug therapy ; Neoplasms* / pathology ; Pyridines* / adverse effects ; Tumor Microenvironment
Keywords
Advanced solid tumors ; Adverse events ; Objective response rate ; Pharmacokinetics ; Sitravatinib
Abstract
Sitravatinib (MGCD516), a spectrum-selective receptor tyrosine kinase inhibitor targeting TAM (TYRO3, AXL, MERTK) and split kinase family receptors, has demonstrated preclinical anti-tumor activity and modulation of tumor microenvironment. This first-in-human phase 1/1b study included sitravatinib dose exploration and anti-tumor activity evaluation in selected patients with advanced solid tumors. Primary objectives included assessment of safety, pharmacokinetics and clinical activity of sitravatinib. Secondary objectives included identifying doses for further investigation and exploring molecular markers for patient selection. In phase 1, 32 patients received 10-200 mg, while phase 1b dose expansion comprised 161 patients (150 mg n = 99, 120 mg n = 62). Maximum tolerated dose was determined as 150 mg daily. Dose-limiting toxicity was reported in 4/28 evaluable phase 1 patients (three at 200 mg, one at 80 mg). In phase 1b, 120 mg was defined as the recommended dose due to tolerability. Treatment-related adverse events (TRAEs) were experienced by 174/193 patients (90.2%); grade ≥ 3 TRAEs in 103 patients (53.4%). Most common TRAEs were diarrhea, fatigue, hypertension and nausea; TRAEs led to treatment discontinuation in 26 patients (13.5%) and death in one patient. Sitravatinib was steadily absorbed and declined from plasma with a terminal elimination half-life of 42.1-51.5 h following oral administration. Overall objective response rate was 11.8% in phase 1b, 13.2% in patients with non-small cell lung cancer (NSCLC) and 4.2% in patients with NSCLC with prior checkpoint inhibitor experience. Sitravatinib demonstrated manageable safety and modest clinical activity in solid tumors. NCT02219711 (first posted August 14, 2014).
Files in This Item:
T202204522.pdf Download
DOI
10.1007/s10637-022-01274-y
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
Yonsei Authors
Cho, Byoung Chul(조병철) ORCID logo https://orcid.org/0000-0002-5562-270X
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/192216
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse

Links